指南与共识肝病

非侵入性检测在临床消化内科实践中识别非酒精性脂肪性肝炎高风险患者的作用:专家小组建议

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
指南 / 共识 · Am J Gastroenterol · 2021-01-01

美国胃肠病学院和慢性肝病基金会的肝病专家针对非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)患者,制定了实用的决策树/算法,用于风险分层以识别纤维化进展期患者。该综述详细描述了算法的开发过程,并为其在胃肠病学/肝病学临床实践中的使用提供建议。

要点

  • 纤维化分期是NAFLD患者肝脏结局的最重要预测因素。
  • 识别纤维化更进展的NAFLD/NASH患者对优化管理至关重要。
  • 专家小组制定了实用的决策树/算法用于NAFLD/NASH风险分层。

核心结论

  • 纤维化分期是NAFLD患者肝脏结局的最重要预测因素,识别进展期纤维化患者对优化管理至关重要。
  • 专家小组制定了实用的决策树/算法,用于在胃肠病学/肝病学临床实践中对NAFLD/NASH进行风险分层。

研究设计与样本

  • 美国胃肠病学院和慢性肝病基金会的肝病专家组成的小组制定了实用的决策树/算法。

主要发现

  • NAFLD/NASH常伴随肥胖、胰岛素抵抗和2型糖尿病等共病,这些共病患病率增加导致NAFLD/NASH患病率在全球、全国甚至儿童中平行增加。
  • 已有多种非侵入性工具可用于诊断和分期NAFLD/NASH,但缺乏简单直接的推荐意见。

临床怎么用

  • 该算法可作为胃肠病学/肝病学临床实践中的资源,用于对NAFLD/NASH患者进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) is generally considered a silent and potentially reversible condition. The subtype of NAFLD that can be classified as nonalcoholic steatohepatitis (NASH) can progress to advanced fibrosis and cirrhosis. Because of the metabolic nature of the pathogenic mechanism underlying NAFLD and NASH, it is often accompanied by common comorbidities such as obesity, insulin resistance, and type 2 diabetes mellitus. The increase in the prevalence of these comorbidities has resulted in a parallel increase in the prevalence of NAFLD and NASH, globally, nationally, and even in children. In recent years, it has been identified that the stage of fibrosis is the most important predictor of liver outcomes; therefore, identifying patients with NAFLD and NASH with more advanced stages of fibrosis can be essential for optimal management. Several noninvasive tools for diagnosing and staging NAFLD and NASH are available, but simple and straightforward recommendations on the use of these tools are not. Recognizing these unmet needs, hepatologists who are members of the American College of Gastroenterology and the Chronic Liver Disease Foundation created a practical decision tree/algorithm to risk stratify NAFLD/NASH as a resource in gastroenterology/hepatology clinical practices. This review will provide insight into how this algorithm was developed, describe it in detail, and provide recommendations for its use in clinical practice.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Noureddin M, Bernstein D, et al. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol. 2021. PMID: 33284184. doi:10.14309/ajg.0000000000001054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。